News - TOSP

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

BERGENBIO RAISES NOK500M (€45.4M) VIA AN OVER SUBSCRIBED PRIVATE PLACEMENT

05 May 2020

Bergen, Norway, 5 May 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, is pleased to announce that it has raised NOK500m (gross) (€45.4 million) via an over subscribed Private Placement that took place via an accelerated book building process after close of market on 4 May 2020. The Offering was made through the allocation of 13,325,000... Read more

Scancell Holdings – Development of vaccine against COVID-19

24 Apr 2020

24 April 2020 Scancell Holdings plc (“Scancell” or the “Company”) Scancell to initiate development of novel DNA vaccine against COVID-19 Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that it has initiated a research programme to develop a vaccine for COVID-19. The project will be led by Professor Lindy Durrant, Chief Scientific Officer and Professor of Cancer Immunotherapy at the... Read more

Firms at The Oxford Science Park playing important role in COVID-19 response

20 Apr 2020

Firms at The Oxford Science Park playing important role in COVID-19 response From immunology research tools and sequencing to AI and cloud telephony Oxford, UK, April 20 2020 – Several occupiers at The Oxford Science Park, one of the UK’s leading parks for science and technology companies, are involved in the response to the COVID-19 epidemic, including important R&D and clinical support services. Part of the broader crisis response across... Read more

Exscientia – joint initiative to identify COVID-19 drugs with Diamond Light Source & Scripps Research

31 Mar 2020

Exscientia announces joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research · Transatlantic partnership seeks to identify COVID-19 antiviral treatments · Exscientia to screen nearly every known approved and investigational drug – 15,000 clinical molecules – against key COVID-19 drug targets to progress rapid treatments Exscientia,... Read more

Lilly and Sitryx Announce Licensing & Research Collaboration to Discover & Develop New Immunometabolic Medicines

31 Mar 2020

Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and... Read more